NCT01431833View on ClinicalTrials.gov

A PK and Safety Study in Subjects With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

May 31, 2012

Study Completion Date

May 31, 2012

Conditions
Hepatic Impairment
Interventions
DRUG

TR-701 FA

Oral single dose 200 mg

Trial Locations (2)

32809

Trius Investigator Site 001, Orlando

55404

Trius Investigator Site 002, Minneapolis

All Listed Sponsors
lead

Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

INDUSTRY

NCT01431833 - A PK and Safety Study in Subjects With Hepatic Impairment | Biotech Hunter | Biotech Hunter